This study evaluates the feasibility and safety of dasatinib plus quercetin (DQ) in patients with idiopathic pulmonary fibrosis (IPF). Fourteen participants with stable IPF were enrolled in a two-center, open-label pilot study. The primary endpoints were retention and completion rates for planned clinical assessments, while secondary endpoints included safety and changes in functional and health measures. DQ was administered intermittently over three weeks, with three doses on three consecutive days followed by four-day breaks. The retention rate was 100%, and all planned assessments were completed by 13 participants. One serious adverse event was reported, and most non-serious events were mild to moderate. Physical function measures, such as 6-minute walk distance, gait speed, and chair-stands time, showed significant and clinically meaningful improvements. Pulmonary function, clinical chemistries, frailty index, and reported health remained unchanged. While effects on circulating senescence-associated secretory phenotype (SASP) factors were inconclusive, correlations were observed between changes in function and SASP-related markers. This study supports the feasibility of larger randomized controlled trials to evaluate the potential of senolytics in treating IPF and other senescence-related diseases.This study evaluates the feasibility and safety of dasatinib plus quercetin (DQ) in patients with idiopathic pulmonary fibrosis (IPF). Fourteen participants with stable IPF were enrolled in a two-center, open-label pilot study. The primary endpoints were retention and completion rates for planned clinical assessments, while secondary endpoints included safety and changes in functional and health measures. DQ was administered intermittently over three weeks, with three doses on three consecutive days followed by four-day breaks. The retention rate was 100%, and all planned assessments were completed by 13 participants. One serious adverse event was reported, and most non-serious events were mild to moderate. Physical function measures, such as 6-minute walk distance, gait speed, and chair-stands time, showed significant and clinically meaningful improvements. Pulmonary function, clinical chemistries, frailty index, and reported health remained unchanged. While effects on circulating senescence-associated secretory phenotype (SASP) factors were inconclusive, correlations were observed between changes in function and SASP-related markers. This study supports the feasibility of larger randomized controlled trials to evaluate the potential of senolytics in treating IPF and other senescence-related diseases.